Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safeguard Jumps Into Life Science But Leaves Behind Early-Stage Risk

This article was originally published in Start Up

Executive Summary

With two major exits and a third pending, the traditionally high-tech-heavy investor's new strategy is paying off. Safeguard's lower appetite for risk in the life sciences means focusing on companies with existing or near-term revenues, cash flow, and net worth being built up, rather than dependence on a regulatory or clinical milestone as an inflection point. The firm also boasts an ability to bolster the management and operational capabilities of its young companies.
Advertisement

Related Content

Delivering Cancer Diagnostics Tools
Delivering Cancer Diagnostics Tools
What's Fueling The Recent Diagnostics Dealmaking?
What's Fueling The Recent Diagnostics Dealmaking?
GE Acquires Clarient To Anchor Its Molecular IVD Business
GE Acquires Clarient To Anchor Its Molecular IVD Business
Good Start Genetics Raises $18 Million For Sequencing-Based Testing
Good Start Genetics Raises $18 Million For Sequencing-Based Testing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel